RT Journal Article
SR Electronic
T1 <em>De novo</em> variants in <em>SNAP25</em> cause an early-onset developmental and epileptic encephalopathy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.11.20095141
DO 10.1101/2020.05.11.20095141
A1 Chiara Klöckner
A1 Heinrich Sticht
A1 Pia Zacher
A1 Bernt Popp
A1 Dewi P. Bakker
A1 Katy Barwick
A1 Michaela V. Bonfert
A1 Eva H. Brilstra
A1 Care4Rare Canada Consortium
A1 Wendy K. Chung
A1 Angus J. Clarke
A1 Patrick Devine
A1 Jennifer Friedman
A1 Alyssa Gates
A1 Gabriella Horvath
A1 Jennifer Keller-Ramey
A1 Boris Keren
A1 Manju A. Kurian
A1 Virgina Lee
A1 Kathleen A. Leppig
A1 Johan Lundgren
A1 Marie T. McDonald
A1 Amy McTague
A1 Heather C. Mefford
A1 Cyril Mignot
A1 Mohamad A. Mikati
A1 Caroline Nava
A1 F. Lucy Raymond
A1 Julian R. Sampson
A1 Alba Sanchis-Juan
A1 Vandana Shashi
A1 Joseph T.C. Shieh
A1 Marwan Shinawi
A1 Anne Slavotinek
A1 Tommy Stödberg
A1 Nicholas Stong
A1 Jennifer A. Sullivan
A1 Ashley C. Taylor
A1 Tomi L. Toler
A1 Marie-José van den Bogaard
A1 Saskia N. van der Crabben
A1 Koen van Gassen
A1 Richard H. van Jaarsveld
A1 Jessica Van Ziffle
A1 Alexandrea F. Wadley
A1 Matias Wagner
A1 Saskia B. Wortmann
A1 Rikke S. Møller
A1 Johannes R. Lemke
A1 Konrad Platzer
YR 2020
UL http://medrxiv.org/content/early/2020/05/15/2020.05.11.20095141.abstract
AB Purpose This study aims to provide the first comprehensive description of the phenotypic and genotypic spectrum of SNAP25 developmental and epileptic encephalopathy (SNAP25- DEE) by reviewing newly identified and previously reported individuals.Methods Individuals harboring heterozygous missense or truncating variants in SNAP25 were assembled through collaboration with international colleagues, matchmaking platforms and literature review. For each individual, detailed phenotyping, classification and structural modeling of the identified variant was performed.Results The cohort comprises 20 individuals with (likely) pathogenic de novo variants in SNAP25. Intellectual disability and early-onset epilepsy were identified as the core symptoms of SNAP25-DEE, with recurrent findings of movement disorders, cortical visual impairment and brain atrophy. Structural modeling for all variants predicted possible functional defects concerning SNAP25 or impaired interaction with other components of the SNARE complex.Conclusion We provide a first comprehensive description of SNAP25-DEE with intellectual disability and early onset epilepsy mostly occurring before the age of two years. These core symptoms and additional recurrent phenotypes show an overlap to genes encoding other components or associated proteins of the SNARE complex such as STX1B, STXBP1 or VAMP2. Thus, these findings advance the concept of a group of neurodevelopmental disorders that may be termed “SNAREopathies”.Competing Interest StatementJKR is an employee of GeneDx, Inc. The other authors declare no conflicts of interest.Funding StatementWork on individual 5 was supported in part by grants from SFARI and the JPB Foundation. AM, KB and MAK are funded by the NIHR GOSH BRC. Individual 7 was enrolled in the NIHR BioResource research study, supported by the Cambridge Biomedical Research Centre and the National Institute for Health Research (NIHR) for the NIHR BioResource (grant number RG65966). Funding for the Duke Genome Sequencing Clinic which is supported by the Duke University Health System. Individual V6 was enrolled in Care4Rare Canada Consortium, funded by Genome Canada, Ontario Genomics Institute (OGI-147), Canadian Institutes of Health Research, Ontario Research Fund, Genome Alberta, Genome British Columbia, BC Children’s Hospital Foundation, BC Children’s Hospital Research Institute, BC Provincial Health Services Authority, Genome Quebec, and Children’s Hospital of Eastern Ontario Foundation. This study makes use of data generated by the DECIPHER Consortium. A full list of centres who contributed to the generation of the data is available from https://decipher.sanger.ac.uk/ and via email from decipher{at}sanger.ac.uk. Funding for the project was provided by the Wellcome Trust. R.S.M. was supported by a grant from the Lundbeck Foundation (R277-2018-802). Research reported in this publication was supported by the National Human Genome Research Institute of the National Institutes of Health under Award Number U01HG009599.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data and methods are reported in the article and in the supplement.